Pfizer (PFE)
(Real Time Quote from BATS)
$25.70 USD
+0.30 (1.18%)
Updated Apr 29, 2024 01:04 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Pfizer Inc. [PFE]
Reports for Purchase
Showing records 541 - 554 ( 554 total )
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Despite Headwinds in the U.S. and Europe, Fourth Quarter Revenue Exceeded Expectations
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Management raises guidance for CY10 & maintains earlier guidance for CY12....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Several Factors Held Back Third Quarter Revenue
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Acquisition of Wyeth to ease pressure on topline.Earnings growth to bounce back to respectable levels in CY10, on back of effective cost cutting measures & Wyeth related merger synergies.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
With Wyeth in the Fold, Pfizer is Looking Ahead to Merger Synergies and Life After Lipitor
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S